Activation peptides prolong the murine plasma half-life of human factor VII

Blood

Volumn 117, Issue 12, 2011, Pages 3445-3452

  Johansson, Linda ^a   Karpf, Ditte M ^a   Hansen, Lene ^a   Pelzer, Hermann ^a   Persson, Egon ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEK293; DRUG HALF LIFE; GLYCOSYLATION; HALF LIFE TIME; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN MOTIF; SINGLE DRUG DOSE;

EID: 79953108719     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-290098     Document Type: Article

References (29)

1. Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988;53(4):505-518.
2. Hjort PF, Egeberg O, Mikkelsen S. Turnover of prothrombin, factor VII and factor IX in a patient with hemophilia A. Scand J Clin Lab Invest. 1961;13(4):668-672.
3. Marder VJ, Shulman NR. Clinical aspects of congenital factor VII deficiency. Am J Med. 1964;37(2):182-194.
4. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55(6):638-648. (Pubitemid 24212264)
5. Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol. 2007;65(1):3-11.
6. Thomsen MK, Diness V, Nilsson P, Rasmussen SN, Taylor T, Hedner U. Pharmacokinetics of recombinant factor VIIa in the rat: a comparison of bio-, immuno- and isotope assays. Thromb Haemost. 1993;70(3):458-464. (Pubitemid 23254676)
7. Thomsen MK, Wildgoose P, Nilsson P, Hedner U. Accumulation of the recombinant factor VIIa in rat bone: importance of the Gla-domain and relevance to factor IX, another vitamin K-dependent clotting factor. Pharmacol Toxicol. 1993;73(3):127-132. (Pubitemid 23313598)
8. Petersen LC, Elm T, Ezban M, et al. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors. Thromb Haemost. 2009;101(5):818-826.
9. Biggs R, Denson KWE. The fate of prothrombin and factors VIII, IX and X transfused to patients deficient in these factors. Br J Haematol. 1963;9(4):532-547.
10. Roberts HR, Lechler E, Webster WP, Penick GD. Survival of transfused factor X in patients with Stuart disease. Thromb Diath Haemorrh. 1965;13(2):305-313.
11. Fuchs HE, Pizzo SV. Regulation of factor Xa in vitro in human and mouse plasma and in vivo in mouse: role of the endothelium and plasma proteinase inhibitors. J Clin Invest. 1983;72(6):2041-2049. (Pubitemid 14224410)
12. Narita M, Rudolph AE, Miletich JP, Schwartz AL. The low-density lipoprotein receptor-related protein (LRP) mediates clearance of coagulation factor Xa in vivo. Blood. 1998;91(2):555-560. (Pubitemid 28053378)
13. Weimer T, Wormsbächer W, Kronthaler U, Lang W, Liebing U, Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost. 2008;99(4):659-667. (Pubitemid 351694221)
14. Sørensen BB, Karpf D, Groth AV, et al. Effect of glycoPEGylation on the pharmacokinetic properties of FVIIa. J Thromb Haemost. 2007;5[suppl 2]:abstract P-T-012.
15. Johansen PB, Bjørn SE, Agersø H, et al. Prolonged effect of glycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma. Thromb Haemost. 2010;104(1):157-164.
16. Yatuv R, Dayan I, Carmel-Goren L, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia. 2008;14(3):476-483. (Pubitemid 351638733)
17. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5(9):1904-1913. (Pubitemid 47288949)
18. Persson E, Nielsen LS. Site-directed mutagenesis but not γ-carboxylation of Glu-35 in factor VIIa affects the association with tissue factor. FEBS Lett. 1996;385(3):241-243.
19. Thim L, Bjoern S, Christensen M, et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry. 1988;27(20):7785-7793.
20. 2+ and tissue factor studied using circular dichroism spectroscopy. Protein Sci. 1996;5(8):1531-1540.
21. Smith SA, Morrissey JH. Rapid and efficient incorporation of tissue factor into liposomes. J Thromb Haemost. 2004;2(7):1155-1162. (Pubitemid 40186089)
22. Peng SX, Rockafellow BA, Skedzielewski TM, Huebert ND, Hageman W. Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice. J Pharmaceut Sci. 2009;98(5):1877-1884.
23. Beal SL, Sheiner LB. NONMEM Users Guide Edition 3. University of California-San Francisco, San Francisco, CA: NONMEM Project Group; 2000.
24. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Røjkjær R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood. 2003;102(10):3615-3620. (Pubitemid 37409379)
25. Guéguen P, Cherel G, Badirou I, Denis CV, Christophe OD. Two residues in the activation peptide domain contribute to the half-life of factor X in vivo. J Thromb Haemost. 2010;8(7):1651-1653.
26. Sola RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharmaceut Sci. 2009;98(4):1223-1245.
27. Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharmaceut Sci. 2005;94(8):1626-1635. (Pubitemid 41360859)
28. Rudolph AE, Mullane MP, Porche-Sorbet R, Daust HA, Miletich JP. The role of the factor X activation peptide: a deletion mutagenesis approach. Thromb Haemost. 2002;88(5):756-762. (Pubitemid 35345332)
29. Yang L, Manithody C, Rezaie AR. Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X. J Thromb Haemost. 2009;7(10):1696-1702.